Advertisement
Advertisement
ODTX
Odyssey Therapeutics, Inc. Common Stock
20.00
USDSponsored
+0.85
+4.44%
Nov 10, 15:59 UTC -5
Closed
After-Market
20.00
0.00
-0.02%
Odyssey Therapeutics, Inc. Common Stock (ODTX) Earnings
ODTX Earnings Reports
Positive Surprise Ratio
ODTX beat 0 of 3 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Odyssey Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 04, 2026, ODTX reported earnings of -1.10 USD per share (EPS) for Q3 26, missing the estimate of -1.09 USD, resulting in a -0.26% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -9.60% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Odyssey Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Odyssey Therapeutics, Inc. Common Stock reported EPS of -$1.10, missing estimates by -0.26%, and revenue of $0.00, 0% as expectations.
How did the market react to Odyssey Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -9.6%, changed from $21.57 before the earnings release to $19.50 the day after.
When is Odyssey Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Odyssey Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Odyssey Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.